Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma
about
Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expressionMDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma.Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesotheliomaRechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer.The maize brown midrib4 (bm4) gene encodes a functional folylpolyglutamate synthasePhase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17).Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome.Telomere length kinetics assay (TELKA) sorts the telomere length maintenance (tlm) mutants into functional groups.Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer.Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
P2860
Q26747641-EDC21336-261E-4E62-8FBC-482F4C33E8EAQ27853125-01005D02-7A1E-48E7-A366-03DEDD0ECD0EQ33831942-80A6FFDB-2D60-4847-8195-185D5CEEFBD4Q33914000-7C630C1F-28F8-44D8-8665-5F63CBF74E3AQ34265773-B48D8F83-62AB-4160-8BB7-F686D039E587Q35086787-C138CC87-26EF-42A3-A005-554ADE9FE43DQ35677288-ACEB700B-51AB-4F8B-AEDA-8F7E3717D4F4Q36696282-8DD73292-187B-4162-AD47-0628D389A0A9Q36821156-482A4B2F-C98C-440D-B458-8C1B0C45EDE8Q37190264-16B8166A-49B6-4636-9F8E-17E50A34E194Q40164385-542125D8-6E3D-4297-8A2A-BFA29DA7E746Q52717613-91131521-3316-466C-9A0E-D0C838B15023Q56976088-27FAE99A-E892-47EB-8CAF-6F1AC6465168
P2860
Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Folylpoly-glutamate synthetase ...... malignant pleural mesothelioma
@en
type
label
Folylpoly-glutamate synthetase ...... malignant pleural mesothelioma
@en
prefLabel
Folylpoly-glutamate synthetase ...... malignant pleural mesothelioma
@en
P2093
P2860
P1476
Folylpoly-glutamate synthetase ...... malignant pleural mesothelioma
@en
P2093
Andrea Tannapfel
Bernadette Reyna Asuncion
Celine Mascaux
Cindy Tran
Daniel C Christoph
Dirk Theegarten
Fred R Hirsch
Georgios Stamatis
Jeremias Wohlschlaeger
Martin Schuler
P2860
P304
P356
10.1097/JTO.0B013E318260DEAA
P577
2012-09-01T00:00:00Z